The evaluation of hTERT mRNA expression in acute leukemia children and 2 years follow-up of 40 cases

International Journal of Hematology

Volumn 87, Issue 3, 2008, Pages 276-283

  Cogulu, Ozgur ^a   Kosova, Buket ^a   Gunduz, Cumhur ^a   Karaca, Emin ^a   Aksoylar, Serap ^a   Erbay, Ayse ^b   Karapinar, Deniz ^a   Vergin, Canan ^b   Vural, Filiz ^a   Tombuloglu, Murat ^a   Cetingul, Nazan ^a   Ozkinay, Ferda ^a  

^a EGE UNIVERSITY   (Turkey)

^b Behcet Uz Children's Hospital   (Turkey)

Author keywords

Children; Leukemia; Prognosis; Telomerase

Indexed keywords

HEMOGLOBIN; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; BONE MARROW; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; T LYMPHOCYTE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RNA, MESSENGER; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 46149089189     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0054-y     Document Type: Article

References (24)

1. Dhaene K, Van Marck E, Parwaresch R. Telomeres, telomerase and cancer: an up-date. Virchows Arch. 2000;437:1-16.
2. Iwama H, Ohyashiki K, Ohyashiki JH, et al. Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum Genet. 1998;102:397-402.
3. Granger MP, Wright WE, Shay JW. Telomerase in cancer and aging. Crit Rev Oncol Hematol. 2002;41:29-40.
4. Polychronopoulou S, Koutroumba P. Telomere length and telomerase activity: variations with advancing age and potential role in childhood malignancies. J Pediatr Hematol Oncol. 2004;26:342-50.
5. Beksac M, Onur ND. Telomerase activity in hematologic malignancies and predisposing diseases. Turk J Hematol. 2001;18:5-17.
6. Huh HJ, Huh JW, Yoo ES, et al. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol. 2005;79:267-73.
7. Drummond MW, Balabanov S, Holyoake TL, Brummendorf TH. Concise review: telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells. 2007;25:1853-61.
8. Verstovsek S, Manshouri T, Smith FO, et al. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer 2003;97:2212-7.
9. Bechter OE, Eisterer W, Pall G, Hilbe W, Kühr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4918-22.
10. Kubuki Y, Suzuki M, Sasaki H, et al. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma 2005;46:393-9.
11. Verstovsek S, Giles FJ, O'Brien S, et al. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res. 2004;28:707-11.
12. Li X, Wang X, Li X, Liu B, Zhang Y, Liao Q. Studies of hTERT gene expression in acute leukemia children. Sichuan Da Xue Xue Bao Yi Xue Ban 2003;34:486-8.
13. Cogulu O, Kosova B, Karaca E, et al. Evaluation of telomerase mRNA (hTERT) in childhood acute leukemia. Leuk Lymphoma 2004;45:2477-80.
14. Terrin L, Trentin L, Degan M, et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same IgVH mutation status and different outcome. Leukemia 2007;21:965-72.
15. Tchirkov A, Chaleteix C, Magnac C, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol. 2004;15:1476-80.
16. Seol JG, Kim ES, Park WH, Jung CW, Kim BK, Lee YY. Telomerase activity in acute myelogenous leukaemia: clinical and biological implications. Br J Haematol. 1998;100:156-65.
17. Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW. Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res. 1997;3:619-25.
18. Martens UM, Brass V, Engelhardt M, et al. Measurement of telomere length in haematopoietic cells using in situ hybridization techniques. Biochem Soc Trans. 2000;28:245-50.
19. Tukun A, Gumus GG, Kutlay NY. Telomere and telomerase in hematological malignancies. Turk J Hematol. 2006;23:77-83.
20. Effros RB. Replicative senescence in the immune system: impact of the Hayflick limit on T-cell function in the elderly. Am J Hum Genet. 1998;62:1003-7.
21. Xu D, Gruber A, Peterson C, Pisa P. Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br J Haematol. 1998;102:1367-75.
22. Zhang W, Piatyszek MA, Kobayashi T, et al. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res. 1996;2:799-803.
23. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995;85:2315-20.
24. Liu L, Sun B, Liang Y. Analysis of telomerase activity and telomere length in acute myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi. 2001;22:592-4.